Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215

Barclays analyst Luke Sergott has maintained an Overweight rating on Twist Bioscience (NASDAQ: TWST) and raised the price target significantly from $112 to $215. This adjustment reflects a positive outlook on the company's performance.